 [1m([0morchestrator-acute liver injury-PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes PHENYTOIN SODIUM increase or decrease the risk of acute [0m
[34mliver injury?[0m
 [1m([0morchestrator-acute liver injury-PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-acute liver injury-PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does PHENYTOIN SODIUM increase or decrease the risk of acute liver injury?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-PHENYTOIN SODIUM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes PHENYTOIN SODIUM increase or decrease the risk of acute [0m
[32mliver injury?[0m
 [1m([0morchestrator-acute liver injury-PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-PHENYTOIN SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes PHENYTOIN SODIUM increase or decrease the risk of acute liver injury?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does PHENYTOIN SODIUM increase the risk of acute liver injury?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"PHENYTOIN SODIUM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: PHENYTOIN SODIUM: warnings_and_cautions: The role of other possible factors in the development of, and morbidity from, SJS/TEN, such as antiepileptic drug [0m[1;31m([0m[31mAED[0m[1;31m)[0m[31m dose, compliance, concomitant [0m
[31mmedications, comorbidities, and the level of dermatologic monitoring have not been studied. [0m[1;31m5.4[0m[31m Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m/[0m[31mMultiorgan[0m[31m Hypersensitivity Drug Reaction [0m
[31mwith Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m, also known as Multiorgan Hypersensitivity, has been reported in patients taking antiepileptic drugs, including phenytoin. Some of these events have [0m
[31mbeen fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling, in association with other organ system involvement, such [0m
[31mas hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection. Eosinophilia is often present. PHENYTOIN SODIUM: warnings_and_cautions: [0m
[31mBecause this disorder is variable in its expression, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or [0m
[31mlymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately. Phenytoin Sodium Injection should be discontinued [0m
[31mif an alternative etiology for the signs or symptoms cannot be established. [0m[1;31m5.5[0m[31m Hypersensitivity Phenytoin and other hydantoins are contraindicated in patients who have experienced phenytoin [0m
[31mhypersensitivity [0m[31m . Additionally, consider alternatives to structurally similar drugs such as carboxamides [0m[1;31m([0m[31me.g., carbamazepine[0m[1;31m)[0m[31m, barbiturates, succinimides, and oxazolidinediones [0m[1;31m([0m[31me.g., [0m
[31mtrimethadione[0m[1;31m)[0m[31m in these same patients. PHENYTOIN SODIUM: warnings_and_cautions: Similarly, if there is a history of hypersensitivity reactions to these structurally similar drugs in the patient or [0m
[31mimmediate family members, consider alternatives to phenytoin. [0m[1;31m5.6[0m[31m Hepatic Injury Cases of acute hepatotoxicity, including infrequent cases of acute hepatic failure, have been reported with phenytoin. [0m
[31mThese events may be part of the spectrum of DRESS or may occur in isolation [0m[31m. Other common manifestations include jaundice, hepatomegaly, elevated serum transaminase levels, leukocytosis, and [0m
[31meosinophilia. The clinical course of acute phenytoin hepatotoxicity ranges from prompt recovery to fatal outcomes. In these patients with acute hepatotoxicity, phenytoin should be immediately [0m
[31mdiscontinued and not re-administered. [0m[1;31m5[0m[31m. PHENYTOIN SODIUM: warnings_and_cautions: [0m[1;31m7[0m[31m Hematopoietic Complications Hematopoietic complications, some fatal, have occasionally been reported in association [0m
[31mwith administration of phenytoin. These have included thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow suppression. There have been a [0m
[31mnumber of reports suggesting a relationship between phenytoin and the development of lymphadenopathy [0m[1;31m([0m[31mlocal or generalized[0m[1;31m)[0m[31m including benign lymph node hyperplasia, pseudolymphoma, lymphoma, and [0m
[31mHodgkin's disease. Although a cause and effect relationship has not been established, the occurrence of lymphadenopathy indicates the need to differentiate such a condition from other types of lymph [0m
[31mnode pathology. Lymph node involvement may occur with or without symptoms and signs resembling DRESS [0m[31m. PHENYTOIN SODIUM: warnings_and_cautions: In all cases of lymphadenopathy, follow-up observation [0m
[31mfor an extended period is indicated and every effort should be made to achieve seizure control using alternative antiepileptic drugs. [0m[1;31m5.8[0m[31m Local Toxicity [0m[1;31m([0m[31mIncluding Purple Glove Syndrome[0m[1;31m)[0m[31m Soft tissue [0m
[31mirritation and inflammation has occurred at the site of injection with and without extravasation of intravenous phenytoin. Edema, discoloration and pain distal to the site of injection [0m[1;31m([0m[31mdescribed as [0m
[31mâ€œpurple glove syndromeâ€[0m[1;31m)[0m[31m have also been reported following peripheral intravenous phenytoin injection. Soft tissue irritation may vary from slight tenderness to extensive necrosis, and sloughing. The [0m
[31msyndrome may not develop for several days after injection. Although resolution of symptoms may be spontaneous, skin necrosis and limb ischemia have occurred and required such interventions as [0m
[31mfasciotomies, skin grafting, and, in rare cases, amputation. PHENYTOIN SODIUM: warnings_and_cautions: Because of the risk of local toxicity, intravenous Phenytoin Sodium Injection should be [0m
[31madministered directly into a large peripheral or central vein through a large-gauge catheter. Prior to the administration, the patency of the IV catheter should be tested with a flush of sterile [0m
[31msaline. Each injection of parenteral Phenytoin Sodium Injection should then be followed by a flush of sterile saline through the same catheter to avoid local venous irritation caused by the alkalinity[0m
[31mof the solution. Intramuscular Phenytoin Sodium Injection administration may cause pain, necrosis, and abscess formation at the injection site [0m[31m . [0m[1;31m5[0m[31m. PHENYTOIN SODIUM: warnings_and_cautions: [0m[1;31m9[0m[31m Renal or[0m
[31mHepatic Impairment or Hypoalbuminemia Because the fraction of unbound phenytoin is increased in patients with renal or hepatic disease, or in those with hypoalbuminemia, the monitoring of phenytoin [0m
[31mserum levels should be based on the unbound fraction in those patients. [0m[1;31m5.10[0m[31m Exacerbation of Porphyria In view of isolated reports associating phenytoin with exacerbation of porphyria, caution should [0m
[31mbe exercised in using this medication in patients suffering from this disease. [0m[1;31m5.11[0m[31m Teratogenicity and Other Harm to the Newborn Phenytoin Sodium Injection may cause fetal harm when administered to a [0m
[31mpregnant woman. Prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse developmental outcomes [0m[31m . PHENYTOIN SODIUM: warnings_and_cautions: Increased [0m
[31mfrequencies of major malformations [0m[1;31m([0m[31msuch as orofacial clefts and cardiac defects[0m[1;31m)[0m[31m, and abnormalities characteristic of fetal hydantoin syndrome, including dysmorphic skull and facial features, nail [0m
[31mand digit hypoplasia, growth abnormalities [0m[1;31m([0m[31mincluding microcephaly[0m[1;31m)[0m[31m, and cognitive deficits, have been reported among children born to epileptic women who took phenytoin alone or in combination with [0m
[31mother antiepileptic drugs during pregnancy. There have been several reported cases of malignancies, including neuroblastoma. A potentially life-threatening bleeding disorder related to decreased [0m
[31mlevels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero. This drug-induced condition can be prevented with vitamin K administration to the mother before [0m
[31mdelivery and to the neonate after birth. [0m[1;31m5.12[0m[31m Hyperglycemia Hyperglycemia, resulting from the drug's inhibitory effect on insulin release, has been reported. PHENYTOIN SODIUM: warnings_and_cautions: [0m
[31mPhenytoin may also raise the serum glucose level in diabetic patients. [0m[1;31m5.13[0m[31m Serum Phenytoin Levels Above Therapeutic Range Serum levels of phenytoin sustained above the therapeutic range may produce [0m
[31mconfusional states referred to as [0m[31m"delirium"[0m[31m, [0m[31m"psychosis"[0m[31m, or [0m[31m"encephalopathy"[0m[31m, or rarely irreversible cerebellar dysfunction and/or cerebellar atrophy. Accordingly, at the first sign of acute [0m
[31mtoxicity, serum levels should be immediately checked. Dose reduction of phenytoin therapy is indicated if serum levels are excessive; if symptoms persist, termination is recommended.         [0m
[31mSOURCE:PHENYTOIN SODIUM label[0m


[31mCONTENT: PHENYTOIN SODIUM: adverse_reactions: [0m[1;31m6[0m[31m ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling: Cardiovascular Risk Associated with Rapid Infusion [0m[31m [0m
[31mWithdrawal Precipitated Seizure, Status Epilepticus [0m[31m Serious Dermatologic Reactions [0m[31m Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m/[0m[31mMultiorgan[0m[31m Hypersensitivity [0m[31m Hypersensitivity [0m[31m [0m
[31mHepatic Injury [0m[31m Hematopoietic Complications [0m[31m Local toxicity [0m[1;31m([0m[31mIncluding Purple Glove Syndrome[0m[1;31m)[0m[31m [0m[31m Exacerbation of Porphyria [0m[31m Teratogenicity and Other Harm to the Newborn [0m[31m Hyperglycemia [0m[31m The following [0m
[31madverse reactions associated with the use of Phenytoin Sodium Injection were identified in clinical studies or postmarketing reports. Because these reactions are reported voluntarily from a population[0m
[31mof uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The most notable signs of toxicity associated with the [0m
[31mintravenous use of this drug are cardiovascular collapse and/or CNS depression. Hypotension does occur when the drug is administered rapidly by the intravenous route. PHENYTOIN SODIUM: [0m
[31madverse_reactions: The rate of administration is very important; it should not exceed [0m[1;31m50[0m[31m mg per minute in adults, and [0m[1;31m1[0m[31m to [0m[1;31m3[0m[31m mg/kg/min [0m[1;31m([0m[31mor [0m[1;31m50[0m[31m mg per minute, whichever is slower[0m[1;31m)[0m[31m in pediatric patients [0m
[31m. Body As a Whole: Allergic reactions in the form of rash and rarely more serious forms [0m[1;31m([0m[31msee Skin and Appendages paragraph below[0m[1;31m)[0m[31m and DRESS [0m[31m have been observed. Anaphylaxis has also been reported. [0m
[31mThere have also been reports of coarsening of facial features, systemic lupus erythematosus, periarteritis nodosa, and immunoglobulin abnormalities. Cardiovascular: Severe cardiovascular events and [0m
[31mfatalities have been reported with atrial and ventricular conduction depression and ventricular fibrillation. PHENYTOIN SODIUM: adverse_reactions: Severe complications are most commonly encountered in[0m
[31melderly or critically ill patients [0m[31m . Digestive System: Acute hepatic failure [0m[31m , toxic hepatitis, liver damage, nausea, vomiting, constipation, enlargement of the lips, and gingival hyperplasia. [0m
[31mHematologic and Lymphatic System: Hematopoietic complications, some fatal, have occasionally been reported in association with administration of phenytoin [0m[31m . These have included thrombocytopenia, [0m
[31mleukopenia, granulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow suppression. While macrocytosis and megaloblastic anemia have occurred, these conditions usually respond to [0m
[31mfolic acid therapy. PHENYTOIN SODIUM: adverse_reactions: Lymphadenopathy, including benign lymph node hyperplasia, pseudolymphoma, lymphoma, and Hodgkin's Disease have been reported [0m[31m. Laboratory Test [0m
[31mAbnormality: Phenytoin may decrease serum concentrations of thyroid hormone [0m[1;31m([0m[31mT4 and T3[0m[1;31m)[0m[31m, sometimes with an accompanying increase in thyroid-stimulating hormone [0m[1;31m([0m[31mTSH[0m[1;31m)[0m[31m, but usually in the absence of [0m
[31mclinical hypothyroidism. Phenytoin may also produce lower than normal values for dexamethasone or metyrapone tests. Phenytoin may also cause increased serum levels of glucose , alkaline phosphatase, [0m
[31mand gamma glutamyl transpeptidase [0m[1;31m([0m[31mGGT[0m[1;31m)[0m[31m. Nervous System: The most common adverse reactions encountered with phenytoin therapy are nervous system reactions and are usually dose-related. PHENYTOIN [0m
[31mSODIUM: adverse_reactions: Reactions include nystagmus, ataxia, slurred speech, decreased coordination, somnolence, and mental confusion. Dizziness, vertigo, insomnia, transient nervousness, motor [0m
[31mtwitchings, paresthesia, and headaches have also been observed. There have also been rare reports of phenytoin induced dyskinesias, including chorea, dystonia, tremor and asterixis, similar to those [0m
[31minduced by phenothiazine and other neuroleptic drugs. Cerebellar atrophy has been reported, and appears more likely in settings of elevated phenytoin levels and/or long-term phenytoin use [0m[31m . A [0m
[31mpredominantly sensory peripheral polyneuropathy has been observed in patients receiving long-term phenytoin therapy. Sk in and Appendages: Dermatological manifestations sometimes accompanied by fever [0m
[31mhave included scarlatiniform or morbilliform rashes.         [0m
[31mSOURCE:PHENYTOIN SODIUM label[0m


[31mCONTENT: PHENYTOIN SODIUM: pharmacokinetics: Distribution Phenytoin is extensively bound to plasma proteins and is prone to competitive displacement. Elimination The serum half-life in man after [0m
[31mintravenous administration ranges from [0m[1;31m10[0m[31m to [0m[1;31m15[0m[31m hours. Metabolism Phenytoin is metabolized by the hepatic cytochrome P450 enzymes CYP2C9 and to a lesser extent by CYP2C19. Excretion Most of the drug [0m
[31mis excreted in the bile as inactive metabolites. Urinary excretion of phenytoin and its metabolites occurs partly by glomerular filtration but, more importantly, by tubular secretion. Specific [0m
[31mPopulations Age: Geriatric Population: Phenytoin clearance tends to decrease with increasing age [0m[1;31m([0m[1;31m20[0m[31m% less in patients over [0m[1;31m70[0m[31m years of age relative to that in patients [0m[1;31m20[0m[31m to [0m[1;31m30[0m[31m years of age[0m[1;31m)[0m[31m. [0m
[31mPHENYTOIN SODIUM: pharmacokinetics: Since phenytoin clearance is decreased slightly in elderly patients, lower or less frequent dosing may be required [0m[31m. S e x [0m[31m/[0m[31mRace[0m[31m: Gender and race have no [0m
[31msignificant impact on phenytoin pharmacokinetics. Renal or Hepatic Impairment: Increased fraction of unbound phenytoin in patients with renal or hepatic disease, or in those with hypoalbuminemia has [0m
[31mbeen reported. P regnancy: It has been reported in the literature that the plasma clearance of phenytoin generally increased during pregnancy, reached a peak in the third trimester and returned to the[0m
[31mlevel of pre-pregnancy after few weeks or months of delivery. Drug Interaction Studies Phenytoin is primarily metabolized by the cytochrome P450 enzymes CYP2C9 and to a lesser extent by CYP2C19. [0m
[31mPHENYTOIN SODIUM: pharmacokinetics: Phenytoin is a potent inducer of hepatic drug-metabolizing enzymes [0m[31m .         [0m
[31mSOURCE:PHENYTOIN SODIUM label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: PHENYTOIN SODIUM can increase the risk of acute liver injury. Cases of acute hepatotoxicity, including infrequent cases of acute hepatic failure, have been reported with phenytoin. These [0m
[32mevents may be part of the spectrum of DRESS [0m[1;32m([0m[32mDrug Reaction with Eosinophilia and Systemic Symptoms[0m[1;32m)[0m[32m or may occur in isolation. Manifestations include jaundice, hepatomegaly, elevated serum [0m
[32mtransaminase levels, leukocytosis, and eosinophilia. The clinical course of acute phenytoin hepatotoxicity ranges from prompt recovery to fatal outcomes. In patients with acute hepatotoxicity, [0m
[32mphenytoin should be immediately discontinued and not re-administered.[0m

[32mSOURCE: PHENYTOIN SODIUM label[0m
[32mEXTRACT_START_END: Cases of acute hepatotoxicity[0m[32m...[0m[32m not re-administered.[0m
*[1m([0morchestrator-acute liver injury-PHENYTOIN SODIUM[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: PHENYTOIN SODIUM can increase the risk of acute liver [0m
[34minjury. Cases of acute hepatotoxicity, including infrequent cases of acute hepatic failure, have been reported with phenytoin. These events may be part of the spectrum of DRESS [0m[1;34m([0m[34mDrug Reaction with [0m
[34mEosinophilia and Systemic Symptoms[0m[1;34m)[0m[34m or may occur in isolation. Manifestations include jaundice, hepatomegaly, elevated serum transaminase levels, leukocytosis, and eosinophilia. The clinical course of[0m
[34macute phenytoin hepatotoxicity ranges from prompt recovery to fatal outcomes. In patients with acute hepatotoxicity, phenytoin should be immediately discontinued and not re-administered.[0m

[34mSOURCE: PHENYTOIN SODIUM label[0m
[34mEXTRACT_START_END: Cases of acute hepatotoxicity[0m[34m...[0m[34m not re-administered.[0m
 [1m([0morchestrator-acute liver injury-PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does PHENYTOIN SODIUM increase or decrease the risk of acute liver injury?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether PHENYTOIN SODIUM increases or decreases the risk of acute liver injury."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that PHENYTOIN SODIUM can increase the risk of acute liver injury. Cases of acute hepatotoxicity, including infrequent cases of acute hepatic failure, have been reported [0m
[32mwith phenytoin. These events may be part of the spectrum of DRESS or may occur in isolation, with manifestations including jaundice, hepatomegaly, elevated serum transaminase levels, leukocytosis, and[0m
[32meosinophilia. The clinical course can range from prompt recovery to fatal outcomes, and in cases of acute hepatotoxicity, phenytoin should be immediately discontinued."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"PHENYTOIN SODIUM can increase the risk of acute liver injury."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-acute liver injury-PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-PHENYTOIN SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-acute liver injury-PHENYTOIN SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does PHENYTOIN SODIUM increase or decrease the risk of acute liver injury?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether PHENYTOIN SODIUM increases or decreases the risk of acute liver injury."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that PHENYTOIN SODIUM can increase the risk of acute liver injury. Cases of acute hepatotoxicity, including infrequent cases of acute hepatic failure, have been reported [0m
[34mwith phenytoin. These events may be part of the spectrum of DRESS or may occur in isolation, with manifestations including jaundice, hepatomegaly, elevated serum transaminase levels, leukocytosis, and[0m
[34meosinophilia. The clinical course can range from prompt recovery to fatal outcomes, and in cases of acute hepatotoxicity, phenytoin should be immediately discontinued."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"PHENYTOIN SODIUM can increase the risk of acute liver injury."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does PHENYTOIN SODIUM increase or decrease the risk of acute liver injury?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether PHENYTOIN SODIUM increases or decreases the risk of acute liver injury.[0m
[1;31m2[0m[31m. FDAHandler responded that PHENYTOIN SODIUM can increase the risk of acute liver injury. Cases of acute hepatotoxicity, including infrequent cases of acute hepatic failure, have been reported with [0m
[31mphenytoin. These events may be part of the spectrum of DRESS or may occur in isolation, with manifestations including jaundice, hepatomegaly, elevated serum transaminase levels, leukocytosis, and [0m
[31meosinophilia. The clinical course can range from prompt recovery to fatal outcomes, and in cases of acute hepatotoxicity, phenytoin should be immediately discontinued.[0m
[31m        -----[0m
[31m        Final answer: PHENYTOIN SODIUM can increase the risk of acute liver injury.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-acute liver injury-PHENYTOIN SODIUM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-acute liver injury-PHENYTOIN SODIUM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-acute liver injury-PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-acute liver injury-PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mPHENYTOIN SODIUM can increase the risk of acute liver injury. Cases of acute hepatotoxicity, including infrequent cases of acute hepatic failure, have been reported with phenytoin. These events may be[0m
[32mpart of the spectrum of DRESS [0m[1;32m([0m[32mDrug Reaction with Eosinophilia and Systemic Symptoms[0m[1;32m)[0m[32m or may occur in isolation. Manifestations include jaundice, hepatomegaly, elevated serum transaminase levels, [0m
[32mleukocytosis, and eosinophilia. The clinical course of acute phenytoin hepatotoxicity ranges from prompt recovery to fatal outcomes. In patients with acute hepatotoxicity, phenytoin should be [0m
[32mimmediately discontinued and not re-administered.[0m
